Status:
COMPLETED
Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)
Lead Sponsor:
Istituto Clinico Humanitas
Collaborating Sponsors:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Fondazione Salvatore Maugeri
Conditions:
Pure Autonomic Failure
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with Pure Autonomic ...
Detailed Description
PAF is a rare neurodegenerative disorder characterized by symptoms due to sympathetic failure, such as orthostatic hypotension and syncope, and deficient parasympathetic activity such as constipation,...
Eligibility Criteria
Inclusion
- • Patients, older than 18 years affected by PAF, ALS and POTS, with dysautonomia symptoms assessed by clinical evaluation and by the Composite Autonomic Scoring Scale (CASS)
Exclusion
- Hepatic, renal, heart and other secondary causes of autonomic dysfunction
- History/familiarity with seizures
- Atrial fibrillation and other relevant cardiac rhythm disturbances
- Diabetes
- Other neurological or psychiatric diseases
- Pacemakers or other electronic implants inserted into the body
- Coronary disorders, elevated intracranial blood pressure
- Assumption of drugs facilitating seizures, psychiatric drugs, alcohol abuse
Key Trial Info
Start Date :
April 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2019
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04875949
Start Date
April 1 2016
End Date
April 1 2019
Last Update
May 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Humanitas Research Hospital
Rozzano, Italy, 20089